De Streel at al. demonstrated that their anti-GARP antibody did not display anti-tumour activity when administered as a monotherapy alone in a CT26 tumour mouse model suggesting that the amount of GARP in the tumour may not be sufficient to induce tumour regression. Here, LRRC32 is linked to neoplasm.